Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients.
BACKGROUND
Vesicle-associated membrane protein 2 (VAMP2) is a key component of the synaptic vesicle docking/fusion machinery and its mRNA reportedly increases in the frontal cortex of rats following chronic antidepressant and electroconvulsive treatment. VAMP2 is therefore thought to be involved in the mechanism of action of antidepressants and may alter their efficacy. The purpose of this study was to investigate whether the VAMP2 gene is associated with clinical responses to a specific antidepressant, fluvoxamine.


METHODS
A total of 106 patients with major depressive disorder were given fluvoxamine (50-200 mg/day) for 8 weeks and assessed for severity of depression using the Semi-Structured Interview Guide of the Hamilton Depressive Scale (SIGH-D; 17 items) at 0 and 8 weeks. We defined a clinical response as more than a 50% reduction in baseline SIGH-D within 8 weeks, and defined clinical remission as a SIGH-D score of less than 7 at 8 weeks. Genotyping was performed by PCR-RFLP.


RESULTS
Analysis of haplotype tagging single nucleotide polymorphisms as well as haplotype analysis did not reveal any significant associations.


CONCLUSIONS
Our results suggest that the VAMP2 gene is unlikely to play a major role in the efficacy of fluvoxamine.
Saito
Shinichi
S
Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan.
Takahashi
Nagahide
N
Ishihara
Ryoko
R
Ikeda
Masashi
M
Suzuki
Tatsuyo
T
Kitajima
Tsuyoshi
T
Yamanouchi
Yoshio
Y
Iwata
Nakao
N
Yamada
Mitsuhiko
M
Yoshida
Keizo
K
Inada
Toshiya
T
Ozaki
Norio
N
D000328:Adult; D016009:Chi-Square Distribution; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D050988:Vesicle-Associated Membrane Protein 2 / Q000235:genetics*
D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors; D050988:Vesicle-Associated Membrane Protein 2; C494807:VAMP2 protein, human